Association between hashimoto thyroiditis and differentiated thyroid cancer: A single-center experience.
differentiated thyroid cancer
hashimoto thyroiditis
papillary thyroid cancer
thyroid
thyroid surgery
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
06
2022
accepted:
30
06
2022
entrez:
15
8
2022
pubmed:
16
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Hashimoto's thyroiditis is the most common cause of hypothyroidism in the iodine-sufficient areas of the world. Differentiated thyroid cancer is the most common thyroid cancer subtype, accounting for more than 95% of cases, and it is considered a tumor with a good prognosis, although a certain number of patients experience a poor clinical outcome. Hashimoto's thyroiditis has been found to coexist with differentiated thyroid cancer in surgical specimens, but the relationship between these two entities has not yet been clarified. Our study aims to analyze the relationship between these two diseases, highlighting the incidence of histological diagnosis of Hashimoto thyroiditis in differentiated thyroid cancer patients, and assess how this autoimmune disorder influences the risk of structural disease recurrence and recurrence rate.
Identifiants
pubmed: 35965566
doi: 10.3389/fonc.2022.959595
pmc: PMC9366466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
959595Informations de copyright
Copyright © 2022 Cappellacci, Canu, Lai, Lori, Biancu, Boi and Medas.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Med. 2021 Sep 30;10(19):
pubmed: 34640574
BMC Endocr Disord. 2019 May 29;19(Suppl 1):26
pubmed: 31142293
Cancers (Basel). 2019 Aug 22;11(9):
pubmed: 31443531
Int J Surg. 2017 May;41 Suppl 1:S60-S64
pubmed: 28506415
Nutrients. 2021 Dec 14;13(12):
pubmed: 34960019
Acta Otorhinolaryngol Ital. 2017 Oct;37(5):393-400
pubmed: 29165434
Int J Mol Sci. 2020 Dec 15;21(24):
pubmed: 33333840
Cancers (Basel). 2020 Jun 23;12(6):
pubmed: 32585797
Endocr Relat Cancer. 2014 Oct;21(5):797-811
pubmed: 25074669
Braz J Otorhinolaryngol. 2018 Nov - Dec;84(6):729-735
pubmed: 28964693
N Engl J Med. 1985 Mar 7;312(10):601-4
pubmed: 3838363
Clin Endocrinol (Oxf). 2007 Sep;67(3):363-9
pubmed: 17555501
J Endocrinol Invest. 2018 Apr;41(4):395-402
pubmed: 28875268
Eur Thyroid J. 2017 Jul;6(4):178-186
pubmed: 28868258
Front Oncol. 2017 Apr 10;7:53
pubmed: 28443243
Front Endocrinol (Lausanne). 2022 Feb 24;13:801925
pubmed: 35282434
Updates Surg. 2021 Aug;73(4):1467-1475
pubmed: 33861400
PLoS One. 2015 Mar 25;10(3):e0121514
pubmed: 25807528
BJS Open. 2021 Mar 5;5(2):
pubmed: 33688954
JAMA Netw Open. 2021 Jul 1;4(7):e2118526
pubmed: 34313737
Int Immunopharmacol. 2021 Jan;90:107185
pubmed: 33218938
Thyroid Res. 2021 Dec 3;14(1):26
pubmed: 34861884
Virchows Arch. 2013 May;462(5):557-63
pubmed: 23532502
BMC Endocr Disord. 2022 Jan 5;22(1):12
pubmed: 34986823
Biochem Biophys Res Commun. 2011 May 20;408(4):647-53
pubmed: 21531210
Front Endocrinol (Lausanne). 2017 Oct 27;8:290
pubmed: 29163360
J Biol Regul Homeost Agents. 2016 Oct-Dec;30(4):1187-1193
pubmed: 28078873
Cancers (Basel). 2021 Nov 07;13(21):
pubmed: 34771729
Thyroid. 2014 Jul;24(7):1107-14
pubmed: 24708347
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101367
pubmed: 31812326
J Clin Med. 2021 Sep 09;10(18):
pubmed: 34575184
Indian J Surg Oncol. 2022 Mar;13(1):164-168
pubmed: 35462652
Lancet. 2013 Mar 23;381(9871):1058-69
pubmed: 23668556